Table 2 Currently enrolled clinical studies of antiangiogenic immunotherapy combinations for breast cancer (data source: clinicalTrials.gov, Oct 2020)
From: Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment
No | Title | Status | Conditions | Interventions | Locations |
|---|---|---|---|---|---|
1 | A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients with Newly Diagnosed Breast Cancer in Latin America | Recruiting | Breast Cancer | Drug: Bevacizumab, Drug: Trastuzumab, Drug: Ado-trastuzumab emtansine, Drug: Pertuzumab, Drug: Atezolizumab, Drug: Capecitabine | Instituto Alexander Fleming, Buenos Aires, Argentina, and more |
2 | A Multi-cohort Phase II Study of HER2-positive and Triple- negative Breast Cancer Brain Metastases. | Not yet recruiting | Breast Cancer | Drug: Pyrotinib, Drug: Temozolomide Injection, Drug: SHR-1316 (PD-L1), Drug: Bevacizumab, Drug: Cisplatin/Carboplatin | Fudan University Shanghai Cancer Center |
3 | Pre-operative Immunotherapy Combination Strategies in Breast Cancer | Recruiting | Breast Cancer, Estrogen Receptor-positive Breast Cancer | Drug: Atezolizumab, Drug: Cobimetinib, Drug: Ipatasertib, Drug: Bevacizumab | Barts Health NHS Trust, London, United Kingdom |
4 | Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated with Metronomic Vinorelbine | Recruiting | Metastatic Breast Cancer | Drug: Vinorelbine 40 mg, Biological: Toripalimab 240 mg (PD-1), Biological: Bevacizumab 15 mg/kg, Drug: Cyclophosphamide 50 mg, Drug: Capecitabine 500 Mg Oral Tablet, Drug: Cisplatin, Radiation: Hypofractionated radiotherapy | Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China, and more |
5 | SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients with Metastatic Breast Cancer | Active, not recruiting | Metastatic Breast Cancer | Drug: AZD2014, Drug: AZD4547, Drug: AZD5363, Drug: AZD8931, Drug: MEDI4736, Drug: Anthracyclines, Drug: Taxanes, and 12 more | Institut de Couldcérologie de l’Ouest/Paul Papin, Angers, France, and more |
6 | A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients with Metastatic or Inoperable Locally Advanced Triple- Negative Breast Cancer | Recruiting | Triple-negative Breast Cancer | Drug: Capecitabine, Drug: Atezolizumab, Drug: Ipatasertib, Drug: SGN-LIV1A, Drug: Bevacizumab, Drug: Chemotherapy (Gemcitabine + Carboplatin or Eribulin), Drug: Selicrelumab, Drug: Tocilizumab, Drug: Nab-Paclitaxel, Drug: Sacituzumab Govitecould | University of California San Diego Medical Center; Moores Cancer Center, La Jolla, California, United States, and more |
7 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects with TNBC Who Have Progressed on or After Standard-of-care Therapy. | Active, not recruiting | Triple-negative Breast Cancer | Drug: Aldoxorubicin HCl, Biological: N-803, Biological: ETBX-011, Biological: ETBX-051, Biological: ETBX-061, Biological: GI-4000, Biological: GI-6207, Biological: GI-6301, Biological: haNK for Infusion, Biological: avelumab, and 8 more | Chan Soon-Shiong Institute for Medicine, El Segundo, California, United States |
8 | A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer | Recruiting | Breast Neoplasms | Drug: Atezolizumab, Drug: Bevacizumab, Drug: Entinostat, Drug: Exemestane, Drug: Fulvestrant, Drug: Ipatasertib, Drug: Tamoxifen, Drug: Abemaciclib | University of Alabama at Birmingham, Birmingham, Alabama, United States, and more |
9 | Evaluation of IPI-549 Combined with Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3) | Recruiting | Breast Cancer, Renal Cell Carcinoma | Drug: IPI-549, Drug: Atezolizumab, Drug: nab-paclitaxel, Drug: Bevacizumab | Ironwood Cancer and Research Center, Chandler, Arizona, United States, and more |
10 | I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Recruiting | Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma | Drug: Standard Therapy, Drug: AMG 386 with or without Trastuzumab, Drug: AMG 479 (Ganitumab) plus Metformin, Drug: MK-2206 with or without Trastuzumab, Drug: AMG 386 and Trastuzumab, Drug: T-DM1 and Pertuzumab, Drug: Pertuzumab and Trastuzumab, Drug: Ganetespib, Drug: ABT-888, Drug: Neratinib, and 11 more | University of Alabama at Birmingham, Birmingham, Alabama, United States, and more |
11 | A Phase I/II Study of MEDI4736 in Combination with Olaparib in Patients With Advanced Solid Tumors. | Active, not recruiting | Ovarian, Breast, SCLC, Gastric Cancers | Drug: Olaparib, Drug: MEDI4736, Drug: Bevacizumab | Research Site, Newnan, Georgia, United States, and more |